Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331225 · ClinicalTrials.gov registry record
Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
A clinical trial, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- 30
- Enrollment target
NCT02331225 is a clinical trial that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 30 participants.
The verdict
NCT02331225 has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Systemic sclerosis (SSc, also known as scleroderma) is a disease characterized by fibrosis of the skin and organs, inflammation, and an abnormal endothelial cell lining inside of vessels. A common and deadly complication of SSc is pulmonary hypertension (PH), which is an abnormal elevation in the blood pressure within the lung blood vessels. Early identification and treatment of PH is important in SSc, and no clinical factors can predict which patients will develop PH with acceptable accuracy. A potential marker of PH in SSc is the presence of increased amounts of endothelial microparticles (EMPs), which are substances circulating in the blood that were released from damaged vessel wall endothelial lining. A main goal of this study is to investigate if there is a difference in EMP levels between SSc patients with and without PH. The investigators will also use human endothelial cells in a lab environment to test whether these EMPs isolated from SSc patients are actually causing damage to the vessel lining. Lastly, the investigators will investigate the potential benefit of a medication used after transplant, mycophenolate mofetil (MMF). This will be done by causing damage to isolated human endothelial cells and treating them with MMF. The main goal of this portion of our study is to see if EMP levels are reduced when cells are treated with MMF. Overall, the investigators anticipate the following outcomes of this study: 1) use EMP levels to differentiation patients with SSc who have PH from those without PH, 2) use EMPs to understand how endothelial damage occurs in SSc, and 3) use EMPs to help us develop new treatments for patients with vascular diseases.
Interventions
- OTHER No intervention given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02331225
The ClinicalTrials.gov registry entry for NCT02331225 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention given is the first listed.
NCT02331225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02331225 about?
NCT02331225 is a clinical study titled "Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension". Systemic sclerosis (SSc, also known as scleroderma) is a disease characterized by fibrosis of the skin and organs, inflammation, and an abnormal endothelial cell lining inside of vessels. A common and deadly complication of SSc is pulmonary hypertension (PH), which is an abnormal elevation in the bl...
What is the current status of trial NCT02331225?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2014-12. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02331225?
The interventions under investigation include: No intervention given (OTHER).
Who is sponsoring clinical trial NCT02331225?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.